Protective Role of 2,3-Dimethylquinoxaline Against Doxorubicin-Induced Renal Inflammation in Rats via Modulation of the iNOS/COX-2/PGE2/TNF-α/NF-κB Signaling Pathway
International Journal of Pharmacology · 28.06.2026 · 22 (3)
DOI: 10.31083/ijp48537 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Pharmacology, online erschienen am 28.06.2026. Verfasst von Hind AbdulMajed und 18 weiteren Autor:innen. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
A member of the quinoxaline family, 2,3-dimethylquinoxaline (DMQ), has been evaluated for associated nephroprotective properties in an in vivo model system to assess renal inflammation induced by the anticancer drug doxorubicin (DOX).
Methods
Rats were administered DMQ at doses of 30 or 60 mg/kg body weight once daily for 7 consecutive days. Additionally, a single intraperitoneal (i.p.) dose of DOX (15 mg/kg body weight) was administered on the sixth day. DMQ-mediated nephroprotective effects were assessed by measuring renal function markers, oxidative stress markers, lipid peroxidation, renal stress markers, proinflammatory cytokines, and inflammatory mediator levels, as well as by performing histopathological examination of kidney tissues.
Results
DMQ-treated rats exhibited a marked reduction in kidney toxicity markers and restoration of antioxidant enzyme levels, leading to attenuated oxidative stress. DMQ administration also reduced proinflammatory cytokines, renal stress markers, and inflammatory mediators. Furthermore, DMQ may also attenuate DOX-induced renal structural damage and help restore the dilated capsular space and other histopathological alterations in kidney tissues.
Conclusion
These findings suggest that DMQ may protect against DOX-induced renal damage by alleviating oxidative stress and inflammation in a rat model, indicating the potential of DMQ as a nephroprotective agent.
Zitieren
APA
AbdulMajed, H., Helmi, N., Niyazi, H. A., Azhari, A. A., Alhazmi, W., Alkuwaity, K., Alharbi, O., Altalhi, R., Alsufyani, H. A., Alsieni, M., Labban, S., Alharbi, N., Almalki, R. S., Bakheit, K. H., Abu, I., Asiri, T., Alkasih, M. A., Ibrahem, K., & Alfadil, A. (2026). Protective Role of 2,3-Dimethylquinoxaline Against Doxorubicin-Induced Renal Inflammation in Rats via Modulation of the iNOS/COX-2/PGE2/TNF-α/NF-κB Signaling Pathway. International Journal of Pharmacology, 22(3). https://doi.org/10.31083/ijp48537
Vancouver
AbdulMajed H, Helmi N, Niyazi HA, Azhari AA, Alhazmi W, Alkuwaity K, et al. Protective Role of 2,3-Dimethylquinoxaline Against Doxorubicin-Induced Renal Inflammation in Rats via Modulation of the iNOS/COX-2/PGE2/TNF-α/NF-κB Signaling Pathway. International Journal of Pharmacology. 2026;22(3). doi:10.31083/ijp48537
BibTeX
@article{AbdulMajed2026,
author = {AbdulMajed, Hind and Helmi, Noof and Niyazi, Hatoon A. and Azhari, Ala A. and Alhazmi, Wafaa and Alkuwaity, Khalil and Alharbi, Ohood and Altalhi, Rawan and Alsufyani, Hadeel A. and Alsieni, Mohammed and Labban, Samah and Alharbi, Nedaa and Almalki, Riyadh S. and Bakheit, Khalid H and Abu, Ibrahim and Asiri, Turki and Alkasih, Mohannad A and Ibrahem, Karem and Alfadil, Abdelbagi},
title = {Protective Role of 2,3-Dimethylquinoxaline Against Doxorubicin-Induced Renal Inflammation in Rats via Modulation of the iNOS/COX-2/PGE2/TNF-α/NF-κB Signaling Pathway},
journal = {International Journal of Pharmacology},
year = {2026},
volume = {22},
number = {3},
doi = {10.31083/ijp48537}
}
EUVIMED